Par Drugs and Chemicals Limited

NSEI:PAR 株式レポート

時価総額：₹3.6b

Par Drugs and Chemicals バランスシートの健全性

財務の健全性 基準チェック /66

Par Drugs and Chemicalsの総株主資本は₹967.6M 、総負債は₹0.0で、負債比率は0%となります。総資産と総負債はそれぞれ₹1.2Bと₹188.9Mです。 Par Drugs and Chemicalsの EBIT は₹234.0Mで、利息カバレッジ比率-103.9です。現金および短期投資は₹187.8Mです。

主要情報

0%

負債資本比率

₹0

負債

インタレスト・カバレッジ・レシオ-103.9x
現金₹187.82m
エクイティ₹967.61m
負債合計₹188.94m
総資産₹1.16b

財務の健全性に関する最新情報

更新なし

Recent updates

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

財務状況分析

短期負債: PARの 短期資産 ( ₹490.6M ) が 短期負債 ( ₹153.5M ) を超えています。

長期負債: PARの短期資産 ( ₹490.6M ) が 長期負債 ( ₹35.4M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: PARは負債がありません。

負債の削減: PAR負債比率が15.6%であった 5 年前と比べて負債がありません。

債務返済能力: PARには負債がないため、営業キャッシュフロー でカバーする必要はありません。

インタレストカバレッジ: PARには負債がないため、利息支払い の負担は問題になりません。

貸借対照表

健全な企業の発掘

7D

1Y

7D

1Y

7D

1Y